Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
AKBA's Cash-to-Debt is ranked higher than
73% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. AKBA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
AKBA' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: 12424.6
Current: No Debt
N/A
12424.6
Equity-to-Asset 0.17
AKBA's Equity-to-Asset is ranked lower than
92% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AKBA: 0.17 )
Ranked among companies with meaningful Equity-to-Asset only.
AKBA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.14 Max: 0.17
Current: 0.17
0.12
0.17
Interest Coverage No Debt
AKBA's Interest Coverage is ranked higher than
65% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AKBA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AKBA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: -0.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -286.19
AKBA's Operating Margin % is ranked lower than
73% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. AKBA: -286.19 )
Ranked among companies with meaningful Operating Margin % only.
AKBA' s Operating Margin % Range Over the Past 10 Years
Min: -8889.9  Med: -8889.9 Max: -286.19
Current: -286.19
-8889.9
-286.19
Net Margin % -283.95
AKBA's Net Margin % is ranked lower than
75% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. AKBA: -283.95 )
Ranked among companies with meaningful Net Margin % only.
AKBA' s Net Margin % Range Over the Past 10 Years
Min: -8843.45  Med: -8843.45 Max: -283.95
Current: -283.95
-8843.45
-283.95
ROE % -179.91
AKBA's ROE % is ranked lower than
87% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. AKBA: -179.91 )
Ranked among companies with meaningful ROE % only.
AKBA' s ROE % Range Over the Past 10 Years
Min: -179.91  Med: -94.01 Max: -51.66
Current: -179.91
-179.91
-51.66
ROA % -55.60
AKBA's ROA % is ranked lower than
75% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. AKBA: -55.60 )
Ranked among companies with meaningful ROA % only.
AKBA' s ROA % Range Over the Past 10 Years
Min: -365.24  Med: -61.26 Max: -47.82
Current: -55.6
-365.24
-47.82
ROC (Joel Greenblatt) % -5448.50
AKBA's ROC (Joel Greenblatt) % is ranked lower than
84% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. AKBA: -5448.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AKBA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -106220  Med: -24010.07 Max: -5448.5
Current: -5448.5
-106220
-5448.5
3-Year EBITDA Growth Rate -50.20
AKBA's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. AKBA: -50.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AKBA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -51.7  Med: -50.95 Max: -50.2
Current: -50.2
-51.7
-50.2
3-Year EPS without NRI Growth Rate -69.50
AKBA's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. AKBA: -69.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AKBA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.5  Med: -63 Max: -56.5
Current: -69.5
-69.5
-56.5
GuruFocus has detected 2 Warning Signs with Akebia Therapeutics Inc $AKBA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AKBA's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

AKBA Guru Trades in Q3 2016

Jim Simons 151,800 sh (+524.69%)
Paul Tudor Jones 18,410 sh (-2.06%)
» More
Q4 2016

AKBA Guru Trades in Q4 2016

Jim Simons 208,600 sh (+37.42%)
Paul Tudor Jones 19,728 sh (+7.16%)
» More
Q1 2017

AKBA Guru Trades in Q1 2017

Jim Simons 386,267 sh (+85.17%)
Paul Tudor Jones 17,777 sh (-9.89%)
» More
Q2 2017

AKBA Guru Trades in Q2 2017

Jim Simons 1,025,300 sh (+165.44%)
Paul Tudor Jones 12,155 sh (-31.63%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:AKBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ZIOP, NAS:VNDA, NAS:RVNC, NAS:PTCT, NAS:ENTA, NAS:RETA, NAS:EDIT, NAS:CYTK, NAS:ACRS, NAS:TGTX, NAS:INSY, NAS:DOVA, NAS:INSM, NAS:AKAO, NAS:KERX, NAS:ANIK, NAS:ACHN, NAS:LJPC, NAS:SPPI, NAS:RGNX » details
Traded in other countries:AX9.Germany,
Headquarter Location:USA
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology.

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

Ratios

vs
industry
vs
history
PB Ratio 11.27
AKBA's PB Ratio is ranked lower than
92% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. AKBA: 11.27 )
Ranked among companies with meaningful PB Ratio only.
AKBA' s PB Ratio Range Over the Past 10 Years
Min: 9.84  Med: 11.55 Max: 18.08
Current: 11.27
9.84
18.08
PS Ratio 12.23
AKBA's PS Ratio is ranked lower than
68% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. AKBA: 12.23 )
Ranked among companies with meaningful PS Ratio only.
AKBA' s PS Ratio Range Over the Past 10 Years
Min: 10.67  Med: 16.86 Max: 26.49
Current: 12.23
10.67
26.49
Price-to-Free-Cash-Flow 7.35
AKBA's Price-to-Free-Cash-Flow is ranked higher than
64% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. AKBA: 7.35 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AKBA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.42  Med: 12.65 Max: 19.87
Current: 7.35
6.42
19.87
Price-to-Operating-Cash-Flow 7.18
AKBA's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. AKBA: 7.18 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AKBA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.27  Med: 11.41 Max: 17.92
Current: 7.18
6.27
17.92
EV-to-EBIT -2.75
AKBA's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. AKBA: -2.75 )
Ranked among companies with meaningful EV-to-EBIT only.
AKBA' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.76  Med: -1.7 Max: -0.6
Current: -2.75
-2.76
-0.6
EV-to-EBITDA -2.76
AKBA's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. AKBA: -2.76 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKBA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.77  Med: -1.7 Max: -0.6
Current: -2.76
-2.77
-0.6
Current Ratio 1.83
AKBA's Current Ratio is ranked lower than
76% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. AKBA: 1.83 )
Ranked among companies with meaningful Current Ratio only.
AKBA' s Current Ratio Range Over the Past 10 Years
Min: 1.83  Med: 11.62 Max: 26.43
Current: 1.83
1.83
26.43
Quick Ratio 1.83
AKBA's Quick Ratio is ranked lower than
72% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. AKBA: 1.83 )
Ranked among companies with meaningful Quick Ratio only.
AKBA' s Quick Ratio Range Over the Past 10 Years
Min: 1.83  Med: 11.62 Max: 26.43
Current: 1.83
1.83
26.43

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -314.10
AKBA's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. AKBA: -314.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AKBA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -319.9  Med: -317 Max: -314.1
Current: -314.1
-319.9
-314.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 15.58
AKBA's Price-to-Net-Cash is ranked lower than
83% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. AKBA: 15.58 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AKBA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.02  Med: 3.06 Max: 15.6
Current: 15.58
2.02
15.6
Price-to-Net-Current-Asset-Value 12.19
AKBA's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. AKBA: 12.19 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AKBA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.99  Med: 3.01 Max: 13.53
Current: 12.19
1.99
13.53
Price-to-Tangible-Book 11.28
AKBA's Price-to-Tangible-Book is ranked lower than
87% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. AKBA: 11.28 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AKBA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.98  Med: 2.99 Max: 11.68
Current: 11.28
1.98
11.68
Price-to-Median-PS-Value 0.72
AKBA's Price-to-Median-PS-Value is ranked lower than
64% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. AKBA: 0.72 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AKBA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.7  Med: 0.87 Max: 1.01
Current: 0.72
0.7
1.01
Earnings Yield (Greenblatt) % -36.11
AKBA's Earnings Yield (Greenblatt) % is ranked lower than
84% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. AKBA: -36.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AKBA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -155.8  Med: -60 Max: -36.02
Current: -36.11
-155.8
-36.02

More Statistics

Revenue (TTM) (Mil) $49.39
EPS (TTM) $ -3.63
Beta0.86
Short Percentage of Float5.15%
52-Week Range $7.16 - 16.54
Shares Outstanding (Mil)47.15

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 133 140 268
EPS ($) -3.06 -2.13 2.15
EPS without NRI ($) -3.06 -2.13 2.15
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:AKBA

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA Apr 01 2014 

More From Other Websites
Featured Company News - ContraVir Announces Issuance of New US Patent for Expansion of Cyclophilin... Aug 23 2017
Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : August... Aug 14 2017
Akebia Therapeutics reports 2Q loss Aug 08 2017
Akebia Announces Second Quarter 2017 Financial Results Aug 08 2017
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Aug 04 2017
ETFs with exposure to Akebia Therapeutics, Inc. : July 24, 2017 Jul 24 2017
Ex-Akebia employee faces losing bail in insider trading case Jul 20 2017
Akebia Therapeutics, Inc. – Value Analysis (NASDAQ:AKBA) : July 12, 2017 Jul 12 2017
Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : July... Jul 11 2017
Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters Jul 06 2017
Biotech Movers: Akebia Shares Down After Pricing Stock Offering Jun 29 2017
Akebia Announces Pricing of Public Offering of Common Stock Jun 28 2017
Akebia Therapeutics Announces Proposed Public Offering of Common Stock Jun 28 2017
Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017 Jun 20 2017
Akebia Prevails in Two Additional European Patent Disputes Jun 05 2017
Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer May 25 2017
Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to... May 24 2017
Four Stocks Moving On Both News And The Charts May 17 2017
Today's Research Reports on Stocks to Watch: Akebia Therapeutics and xG Technology May 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}